Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma osteopontin levels in multiple sclerosis.

Manuel Comabella1, Imma Pericot, Robert Goertsches

  • 1Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron (HUVH), Escola d'Infermeria 2a planta, Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain. mcomabel@vhebron.net

Journal of Neuroimmunology
|December 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis.

Annals of neurology·2026
Same author

Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.

Brain : a journal of neurology·2026
Same author

Live Attenuated Measles-Mumps-Rubella and Varicella Vaccinations and Multiple Sclerosis Activity.

JAMA network open·2026
Same author

A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.

Frontiers in immunology·2026
Same author

Impact of preanalytical factors on blood CHI3L1 levels.

Frontiers in immunology·2026
Same journal

Clinical features, imaging findings, and treatment outcomes of optic neuritis associated with anti-CRMP5 antibodies: a systematic review.

Journal of neuroimmunology·2026
Same journal

Serum IDO1 and β-catenin levels in patients with multiple sclerosis with and without atherosclerosis: A case-control study.

Journal of neuroimmunology·2026
Same journal

Neurological sequelae of Long COVID: Pathophysiological mechanisms, diagnostic advances, and therapeutic perspectives.

Journal of neuroimmunology·2026
Same journal

Clinical characteristics of IgG4-related hypertrophic pachymeningitis with and without serum ANCA positivity.

Journal of neuroimmunology·2026
Same journal

Chronic neuroinflammation after acute SARS-Cov-2 infection induces retinal damage in the hACE2 transgenic mouse model.

Journal of neuroimmunology·2026
Same journal

Myasthenia gravis misdiagnosis in the era of innovative therapies: Uncovering pitfalls and patterns.

Journal of neuroimmunology·2026
See all related articles

Plasma osteopontin (OPN) levels are elevated in secondary progressive multiple sclerosis (MS) and during relapses in relapsing-remitting MS. OPN may play a role in both acute and chronic MS disease activity.

Area of Science:

  • Neuroimmunology
  • Biochemistry

Background:

  • Osteopontin (OPN) is a protein involved in immunity and inflammation.
  • Previous research suggests OPN's role in experimental autoimmune encephalomyelitis and multiple sclerosis (MS).

Purpose of the Study:

  • To investigate plasma osteopontin (OPN) levels in various multiple sclerosis (MS) phenotypes.
  • To explore the relationship between OPN levels and disease activity or disability progression in MS.

Main Methods:

  • Enzyme-linked immunoassay was used to measure plasma OPN levels.
  • Study included 221 MS patients (PP/TP-MS, SPMS, RRMS) and 36 healthy controls.

Main Results:

  • OPN levels were higher in SPMS patients compared to controls, RRMS in remission, and PP/TP-MS patients.

Related Experiment Videos

  • RRMS patients during relapse showed increased OPN levels compared to those in remission.
  • An inverse relationship between OPN levels and disability progression was noted in relapsing MS patients.

    • Conclusions:

    • Osteopontin (OPN) is implicated in both acute and chronic multiple sclerosis (MS) disease activity.
    • OPN levels differ across MS phenotypes, suggesting a complex role in MS pathogenesis.
    • Further research is needed to clarify OPN's specific role in primary progressive MS.